HCHB and element5 form strategic alliance to accelerate the agentic AI movement in post-acute care

Element5’s Agentic AI platform will be integrated with the HCHB EHR

Takeda appoints Rhonda Pacheco President of US Business Unit

Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach

LGC opens CAD $100 million organic chemistry Center of Excellence in Canada

Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients

Dabur's NewU signs Unicommerce to power its omnichannel operations

Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity

Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions

Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases

Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity